TP53 and acute lymphoblastic leukemia: Hypermethylation of genes implicated in the TP53 pathway is a poor independent prognostic factor in patients with ALL and the use of compounds that can directly or indirectly activate this pathway opens new therapeutic strategies for patients with ALL.